AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 17, 2026 Senti announces one-for-thirty-three reverse split Headline · Source: company release
Nasdaq: $SNTIBiotech · Discovery-stage gene circuitsGoing concern · Conditional funding · Listing risk

SNTI Stock Hub: Senti Biosciences Holdings News, Reverse Split and CVRs

Senti transferred SENTI-202 and substantially all former clinical operations on October 21, retaining discovery-stage Rett and TIL programs with no selected development candidate. The one-for-thirty-three split became effective at 5:00 p.m. ET on November 18, with split-adjusted trading expected from the November 19 opening. A November 20 warrant cash-purchase election deadline adds liquidity risk. Separate historical CVRs and conditional future equity funding shape a business with continuing going-concern doubt.

Last updated: November 18, 2026Financial period: September 30, 2026Currency: USD
Research Library · Biotech
Senti Biosciences Holdings: the retained research business, CVRs and capital constraints
Clinical evidence, financial statements, capital structure, governance and risks.
Get the report (PDF)
Next catalyst · Announced corporate event
November 19–20, 2026 · Split-adjusted trading and warrant election deadline

The one-for-thirty-three reverse split became effective at 5:00 p.m. ET on November 18, according to a Form 8-K filed the same day. Split-adjusted Nasdaq trading under the existing SNTI symbol, with new CUSIP 816944201, is expected from the November 19 opening. November 20 is the separate warrant cash-purchase election deadline stated in the quarterly report. Split 8-K · November 18 · Split announcement · Warrant terms and liquidity risks.

The clinical-business sale closed October 21 and the CVR record date was October 30. The next conditional equity funding window is up to $1.8 million by December 31, 2026.

SNTI stock chart

SNTI daily stock chart
Daily chart · Finviz (affiliate link on click). Interactive chart on JC Just Charts.

SNTI stock: dated clinical and financial snapshot

Chart analysis · JC
Technical chart analysis of $SNTI with bull and bear scenarios on JC Just Charts.
October placement
~$2.5M
October 21, 2026 · financing received, not current cash
Future equity commitment
Up to $4.55M
November 9, 2026 · conditional quarterly purchases
Common shares
85,706,263
October 30, 2026 · before the November 18 split
Retained candidates
None selected
November 16 filing · Rett and TIL discovery programs
Historical CVR cap
$60M aggregate
Record date October 30 · three conditional milestones
Warrant election
November 20
2026 · possible cash-purchase demands

Placement and divestiture · Future equity commitment · Shares, candidate status, CVRs and warrant risk. September consolidated cash belongs to the earlier perimeter.

SNTI after the clinical-business sale: early research and funding constraints

Current SNTI shares and historical SENTI-202 CVRs have different economic exposure. The buyer owns the transferred clinical business. Shares acquired after October 30 lack the historical CVR entitlement. The listed company holds early research rights and faces going-concern doubt, conditional funding and possible warrant cash demands.

▲ The constructive case

The completed sale leaves defined Rett and TIL rights, executed support agreements and an affiliate funding commitment. Resolution of cash claims, access to funding and progress toward a selected candidate could give the retained Regulator Dial research a workable development path.

▼ The cautious case

Neither retained program has a selected candidate. Cash resources are limited, future installments depend on conditions, and warrant-purchase claims could exceed available funds. Nasdaq deficiencies, concentrated control and dependence on the former operating company add financial and governance risk.

Latest Senti Biosciences Holdings news

Nov 17, 2026

Senti announces one-for-thirty-three reverse split

Effectiveness is scheduled for November 18, with split-adjusted Nasdaq trading expected from November 19. The share consolidation accompanies continuing bid-price-compliance issues.

Nov 16, 2026

Quarterly filing details retained discovery programs and warrant cash risk

The post-sale holding company has no selected Rett or TIL candidate and retains going-concern doubt. The filing identifies November 20 as the deadline for warrant cash-purchase elections that could consume limited resources.

Nov 10, 2026

New equity commitment provides conditional quarterly funding

A November 9 agreement with CPIF II-9 permits purchases of up to $4.55 million through December 2027, at the company’s option and subject to conditions. The first maximum installment is $1.8 million by December 31, 2026.

Oct 27, 2026

CVR distribution record date fixed for October 30

The board set the close of business on October 30 as the record date for historical contingent rights. Later purchases of common shares do not automatically carry that entitlement.

Oct 26, 2026

Closing filing records divestiture of the clinical business

The October 21 transaction transferred Midco, Opco and substantially all former pipeline to the buyer. The holding company retained specified Rett and TIL rights, entered a consulting agreement and separately raised approximately $2.5 million through a placement.

Sep 24, 2026

Proxy describes Regulator Dial research retained after the proposed sale

The definitive proxy described tamoxifen-responsive reporter experiments and potential Rett and armored TIL applications. Both programs were described as discovery-stage, without selected lead product candidates, under the proposed post-merger plan.

SNTI stock catalysts and development calendar

  • November 18, 2026 — One-for-thirty-three reverse split effective at 5:00 p.m. ET; fractional entitlements rounded up to a whole share. Completed · Form 8-K filed November 18
  • November 19, 2026 — Split-adjusted Nasdaq trading expected from the opening under the SNTI symbol, new CUSIP 816944201. Expected · company filing
  • November 20, 2026 — Deadline identified in the quarterly report for December 2024 warrant purchase elections. Payment follows the contractual timing. Contractual risk event · amount depends on elections and terms
  • By December 31, 2026 — Up to $1.8 million first quarterly equity purchase under the November commitment. Company option · conditions apply
  • February 23, 2027 — Initial bid-price compliance period ends according to the split announcement. Equity deficiency remains separate. Nasdaq deadline · compliance not assured
  • 2027 quarterly windows — Further scheduled equity amounts total up to $2.75 million after the first installment. Conditional funding · not cash received
  • Undated — Candidate selection and possible strategic transactions for the retained Rett/TIL business. Discovery and strategic plans · no IND or patient-readout date

Split effectiveness · Form 8-K · Announced split and bid deadline · Warrant, listing and discovery status · Quarterly funding terms.

Retained research and transferred clinical assets

DISCOVERY · RETAINED

Rett syndrome

Regulator Dial seeks small-molecule control of a potential therapeutic payload. Tamoxifen-responsive reporter experiments support research; no development candidate has been selected and no human study of the retained platform is reported.

DISCOVERY · RETAINED

Armored TILs

The concept uses regulated immune-stimulating payloads such as IL-12 in tumor-infiltrating lymphocytes. Candidate selection, translational evidence and funding remain ahead. Outside collaborators and Opco support the transition.

CLINICAL BUSINESS · TRANSFERRED

SENTI-202

The buyer acquired the former clinical business on October 21. Historical CVRs cover specified SENTI-202 milestones for eligible holders; the listed company received no cash merger consideration.

Scientific descriptions · Current perimeter and development risks · CVR terms.

Post-closing funding and cash obligations

PLACEMENT · COMPLETED

Separate capital receipt

CPIF II-7 subscribed for 7,309,941 pre-split shares on October 21, providing approximately $2.5 million. The $16 million note exchange then expanded common ownership. September cash of $5.553 million preceded the sale.

COMMITMENT · CONDITIONAL

CPIF II-9 funding windows

The November 9 commitment permits up to $4.55 million through quarterly purchases ending December 2027. Continued listing and other conditions apply. The first maximum is $1.8 million by December 31, 2026.

CASH DEMAND RISK

Warrant purchase elections

The filing identifies November 20 as the election deadline under December 2024 warrants. The defined Black-Scholes purchase value could exceed available cash. Management retains substantial doubt about going concern.

Placement and exchange · Commitment · Cash and warrant risks.

Senti Biosciences Holdings deep dive: the full analysis

The full analysis covers the clinical evidence, development milestones, financial statements, cash needs, capital structure, governance and risks. A dated PDF is available in the Research Library.

01 Development scenarios: resources, evidence and the route to a defined business

A constructive operating scenario begins with resolution of near-term cash demands and successful access to equity funding. That would give the company more time to maintain its listing, support outside research and define a candidate-development plan. The retained technology provides two possible application areas, while the assignment and consulting agreements provide a legal and operating framework for work. Progress would need to appear as specific experimental results, candidate decisions and a funded next step.

For the Rett application, a useful evidence sequence would connect a responsive expression system to an appropriate therapeutic payload and disease-relevant effect. For the TIL application, it would connect controllable cytokine output to retained cell activity and acceptable safety characteristics. These are analytical development criteria rather than company-announced dates. A positive platform experiment can justify further work, while candidate nomination and clinical entry require more extensive characterization and resources.

A partnership or licensing transaction offers another possible path. An external party could provide capabilities or capital in exchange for program rights, ownership or participation in economics. The attractiveness of that path depends on the quality and scope of the assigned intellectual property, the state of the experiments and the counterparty’s alternatives. Senti has identified strategic options, but no particular future transaction can be assumed to provide cash or preserve existing holders’ percentage ownership on favorable terms.

A more constrained scenario involves funding-condition failure, material warrant-purchase demands or delayed resolution of listing issues. Cash could then be absorbed by corporate and contractual obligations before the retained programs reach a defined development stage. The company could reduce activity, dispose of rights or pursue a major corporate restructuring. The quarterly report expressly discusses the possibility of dissolution or bankruptcy in adverse circumstances, particularly if liquidity is inadequate for cash obligations.

Competition for the retained programs operates at both scientific and financing levels. Other gene- and cell-therapy approaches can offer different delivery, expression-control or immune-engineering solutions. Senti’s reporter experiments and early payload work are starting points for differentiation, while later evidence must support the intended clinical use. The small company’s ability to fund that work is itself a competitive constraint, since more advanced developers or better-capitalized partners may move faster or offer more mature data.

The CVR route is analytically separate from these operating scenarios. Midco could make progress on SENTI-202 while the listed company pursues a different strategy, and success in a retained discovery program could occur without a CVR payment. For historical rightsholders, milestone eligibility and Midco’s obligations remain central. For current common holders, the important changes are the resources, assets, control and obligations that remain inside the listed issuer. Neither instrument supplies an assured development or financial outcome.

Current risks, program status and strategic alternatives · Scientific development rationale · Assigned rights · Separate contingent rights.

Base scenario — corporate continuity precedes a defined development plan

Merlintrader reading, November 17, 2026: in a middle scenario, Senti implements its announced reverse split and navigates funding decisions while Rett and armored TIL remain discovery programs without selected candidates. Outside research could continue while the company expects no internally conducted R&D for approximately six months. Operating flexibility would depend on actual financing receipts, service costs and any warrant cash-purchase obligations. Conditional commitments provide a possible funding route; going-concern uncertainty remains. The separate CVRs relate to the divested business and provide no assured funding for the listed issuer. This scenario assigns no probability to survival or therapeutic success. Current business and liquidity risks · Conditional equity commitment · Separate Midco CVR obligations.

What would falsify this reading

Merlintrader reading, November 17, 2026: the assessment rests on a fragile holding company with early research rights, conditional funding and unresolved obligations. The following developments would change that reading.

  • Actual funding and the outcome of warrant demands. Disclosed cash receipts and resolution of potential purchases following the November 20 election deadline would clarify available resources. Material claims exceeding accessible funds, or failure to obtain financing, would weaken the continuity case; a funded plan after settling obligations would strengthen it. Warrant rights and going concern.
  • A formal change in listing status. Nasdaq acceptance of a remediation plan or restoration of compliance would reduce a defined corporate risk. A delisting determination would increase constraints. The split became effective at 5:00 p.m. ET on November 18, with adjusted trading expected from November 19; it changes the share unit without independently resolving the separate equity deficiency. Split timetable · Equity deficiency and listing risks.
  • A candidate backed by disease-relevant evidence and resources. Candidate selection, reproducible therapeutic experiments and secured development funding would strengthen the scientific case beyond reporter demonstrations. Failed experiments, loss of required rights or inadequate resources could prevent that transition. No patient-data or approval date is established for the retained programs. Discovery status and development risks.

02 Corporate structure: the holding company, Midco, Opco and the buyer

A holding-company reorganization on April 24, 2026 created the current successor issuer. Senti Biosciences Holdings sat above Senti Holdings, referred to as Midco, which in turn held Senti Biosciences, the operating company or Opco. The reorganization itself preserved the consolidated operating business. The later merger of the purchaser’s subsidiary into Midco was the event that transferred ownership of Midco and its operating subsidiary away from the listed issuer.

That merger closed on October 21 under the agreement signed in July. Midco survived as a subsidiary of the purchaser, ST NewCo Limited, previously named Celadon Partners SPV 35 Limited. These names refer to the same buyer under different names. Opco remained within the acquired structure. Substantially all of the former business and pipeline moved with those companies, including the SENTI-202 clinical program. The listed holding company continues to exist and trade independently of ownership of those subsidiaries.

An executed assignment and license agreement provides the bridge to the retained research business. It assigns specified patents, related rights, know-how and external research agreements supporting the Rett syndrome and Regulator Dial-enabled armored TIL programs. The public company assumes the future obligations attached to assigned contracts, while allocation of accrued obligations follows the agreement. This structure gives the company a defined development perimeter, along with costs and responsibilities necessary to use those rights.

The transferred operating company also provides services back to the holding company. The Master Consulting Agreement covers corporate, administrative, financial, information-technology and operational support, together with research-related services. Its initial term is twelve months, with an option for the company to extend for another twelve. Individual services can be terminated as standalone capabilities develop. The arrangement reduces the immediate need to recreate every function internally, but makes delivery dependent on a related-party counterparty.

The consideration for transferring Midco consisted of contingent rights to future milestone payments. No cash was paid to the listed company or its common stockholders at closing as merger consideration. The approximately $2.5 million placement was a separate capital-raising transaction. This distinction matters to both liquidity and transaction interpretation: the holding company gained funding through issuance, while the sold business created conditional claims for eligible rightsholders rather than an unrestricted cash purchase price for the issuer.

Consolidated financial statements ending September 30 still include the subsidiaries because the reporting date preceded closing. The November quarterly report contains both historical operating descriptions and subsequent-event information about the completed sale. The current business emerges from those subsequent events and the updated risk factors. Historical research spending, cash and assets remain useful for understanding the transition, while the executed contracts determine which rights and obligations belong to the smaller listed entity.

Successor issuer and subsequent events · Closing description · Executed asset assignment · Executed service agreement.

03 SNTI stock catalysts: reverse split, Nasdaq deficiencies and dated obligations

The November 17 announcement specifies a one-for-thirty-three reverse stock split, effective at 5 p.m. on November 18, with split-adjusted Nasdaq trading expected from the opening on November 19. A Form 8-K filed November 18 confirms that the company filed the certificate of amendment and effected the split as of 5:00 p.m. Eastern Time that day, every thirty-three shares being automatically reclassified into one. A reverse split combines multiple existing shares into one share while adjusting the represented ownership unit. It changes the number of shares used in trading and contractual calculations, while the company’s assets and funding needs remain governed by its actual business and obligations.

The quarterly report gives 85,706,263 common shares outstanding on October 30 before the split. Dividing by thirty-three gives approximately 2.597 million before the effect of rounding individual fractional entitlements. The announcement provides for rounding a fractional entitlement upward to a whole share. It also specifies a new CUSIP, 816944201. Par value remains unchanged and, according to the 8-K, the split did not affect the authorized share count. Outstanding options and warrants adjust according to their provisions.

Nasdaq had notified the company on August 27 that its bid had remained below the minimum requirement for the requisite period. The split announcement identifies February 23, 2027 as the end of the initial compliance period and describes a requirement for at least ten consecutive business days at or above the $1 bid threshold. The company is pursuing a structural response to that deficiency, with actual compliance dependent on subsequent trading and Nasdaq’s determination.

A separate notice concerns stockholders’ equity. June 30 equity was a $3.401 million deficit, compared with a $2.5 million continued-listing equity requirement described in the quarterly report. The company submitted a compliance plan on October 12. The November filing says Nasdaq had not accepted the plan. A change in the nominal share unit leaves that accounting requirement as a distinct issue. Any extension, acceptance or formal restoration of compliance would require its own subsequent notice.

The November 20 warrant election deadline sits immediately after the split timetable. The company treats the merger as a Fundamental Transaction under the December 2024 warrants and warns of possible cash-purchase demands. The cash amount follows contractual Black-Scholes inputs, while payment timing follows the warrant terms. This is a different event from investors purchasing shares, holders exercising warrants or the company issuing shares to obtain financing. It can place pressure on resources before a conditional future equity installment is received.

Beyond those dates, the company has optional funding windows under the November commitment and a stated need for additional capital. A financing update, resolution of warrant demands or a strategic transaction could substantially change the resource picture. No precise future clinical-results day accompanies the discovery programs. The practical calendar is therefore driven by implementation, contractual conditions and regulatory listing status, with scientific development milestones requiring further definition.

Split effectiveness · Form 8-K, November 18 · Announced effectiveness, trading and bid-compliance dates · Equity deficiency, warrant rights and share base · Conditional funding timetable.

04 Executive summary: a different business behind the same ticker

The name and ticker connect two materially different stages in Senti’s history. Before the October transaction, Senti financed a clinical cell-therapy program and the infrastructure supporting it. After the transaction, the public holding company holds early research rights, limited financial resources and contractual relationships with its former operating subsidiary. The distinction changes the source of potential value, the cash requirements and the relevance of historical clinical announcements. Current common-share exposure centers on the retained assets and subsequent corporate decisions.

The transaction removed the costs and control associated with the former clinical pipeline from the listed company. It also removed direct ownership of the programs that had generated most of its development visibility. A historical SENTI-202 announcement can therefore affect a qualifying CVR holder’s expectations without creating a corresponding asset inside today’s listed holding company. The separate rights have their own eligibility, payment conditions and counterparty exposure. The economic relationship is narrower than participation in all future clinical or commercial value.

Retained Regulator Dial work offers a scientific direction rather than a near-term registration program. The proposed technology uses an administered small molecule to control expression of a therapeutic payload after a gene or cell therapy has been delivered. Senti describes potential applications in restoring controlled MeCP2 activity for Rett syndrome and regulating immune-stimulating payloads in TIL therapies. The work remains in discovery, with candidate selection, translational validation and development funding still ahead.

Financial capacity is the immediate constraint. The October common-share placement supplied approximately $2.5 million, while existing notes were exchanged into shares. A later commitment offers additional equity funding in specified quarterly amounts, subject to conditions. These arrangements improve access to capital while increasing common-share issuance and the influence of Celadon affiliates. A conditional commitment still leaves the company exposed to failure of a funding condition or an unexpected cash obligation before the next funding date.

The December 2024 warrant provisions add such an obligation. Their transaction-related purchase right uses a contractual Black-Scholes calculation, which can create value even when exercise would be unattractive. The company identifies a November 20 election deadline and warns that aggregate demands could exceed available cash. The distinction between a holder exercising a warrant and requiring its purchase is essential: the first may bring cash into the company, while the second requires cash to leave it.

The reverse split addresses the number of shares represented by each trading unit. It can support an attempt to regain bid-price compliance, while leaving the underlying need for capital, the equity deficiency and development uncertainty in place. A sustainable improvement would require resources, a workable operating plan, progress toward a defined candidate and resolution of listing issues. The completed divestiture provides a new starting structure, but execution of that smaller structure remains the central test.

Current business, liquidity, ownership and warrant risks · Retained-program scientific descriptions · Completed transaction and financing.

05 Regulator Dial and Rett syndrome: controlled expression at discovery stage

Rett syndrome is a neurodevelopmental disorder commonly associated with pathogenic changes in MECP2, which encodes the MeCP2 protein involved in regulation of gene activity. Senti’s retained concept seeks to use Regulator Dial technology as a control layer for a potential gene-oriented treatment. The biological rationale concerns regulation of therapeutic expression after administration. The company has not selected a lead development candidate for this program, so the clinical formulation, delivery system and eventual treatment protocol remain unsettled.

The September proxy describes a tamoxifen-responsive on-switch. In company experiments, adding the control drug to engineered cells increased expression of a reporter gene. The example uses mCherry, a fluorescent reporter, to show that the engineered control system can respond to the external signal. Senti proposes adapting that type of system to a payload such as MeCP2. Reporter expression demonstrates a component function; restoration of clinically useful function in a patient requires a much broader package of evidence.

Senti also describes engineering its drug-response system for greater sensitivity at low tamoxifen concentrations. The rationale is to place gene-expression control within drug concentrations relevant to potential use in people, including exposure in the brain. This is a technical design goal. The fact that tamoxifen already has approved medical uses concerns the control drug’s existing indications. A new gene-therapy construct using that control mechanism would have its own manufacturing, pharmacology, safety and regulatory requirements.

A mouse experiment described in the proxy uses luciferase as the regulated reporter. Luciferase generates a measurable signal that permits observation of expression after administration of the control drug. The reported increase supports activity of the switch in that experimental setting. The therapeutic payload would differ from the reporter, and the relationship among drug exposure, expression in relevant cells, persistence and biological effect would need further study. The proxy provides a platform demonstration rather than a treatment dataset in Rett patients.

The attraction of a controllable system is that delivery of a gene-oriented therapy and adjustment of its activity become separate steps. In principle, a clinician could alter a control-drug regimen after the therapeutic construct has been administered. The desired control must also be predictable, reproducible and sufficiently selective in the relevant tissues. A switch that responds in a laboratory assay may behave differently across cell types, exposure levels and disease conditions. Those are development questions for Senti’s proposed application.

The November risk factors describe Regulator Dial experiments only in laboratory systems and animal models, with no human testing. Delivery must place both a therapeutic gene and its control system in the appropriate cells. For Rett syndrome, the intended tissue includes the central nervous system. Senti specifically identifies the risk of too much or too little MeCP2 expression, as well as the challenge of maintaining adequate control over time. These requirements connect the molecular switch to tissue delivery and long-term function rather than to reporter intensity alone.

The control drug would also be part of the treatment burden. Senti notes that prolonged administration could carry safety concerns or prove unacceptable to regulators, physicians or patients, with children particularly relevant to the Rett setting. The prospect of adjusting expression offers flexibility, while repeated control-drug exposure introduces a second pharmacologic component requiring characterization. The company identifies potential vector immune responses, liver toxicity, off-target effects and cytokine toxicities among broader gene- and cell-therapy risks. Those are development risks, rather than observed patient events from Senti’s retained programs.

The company expects outside collaborators to continue testing aspects of its Regulator Dial platform over approximately six to nine months, while it expects no internally conducted research and development for approximately six months. These are descriptions of research organization, not an IND schedule. The meaningful scientific milestones would be a defined candidate, convincing disease-relevant evidence, an exposure and safety package, a reproducible manufacturing approach and resources to move the program forward. The November materials attach no firm patient-data or approval date to that sequence.

Rett rationale and tamoxifen-controlled experiments · Discovery status and research operating plan · Rett disease background.

06 Armored TIL research: regulating immune payloads in solid tumors

The second retained program applies Regulator Dial technology to armored tumor-infiltrating lymphocytes. TILs are immune cells found within a tumor that can be isolated and expanded for therapeutic use. Senti’s proposed contribution is an engineered control system for additional payload expression. This is a different modality and development question from the former off-the-shelf CAR-NK program. The shared use of synthetic biology connects the research approaches, while the products, manufacturing and supporting evidence are distinct.

In the proxy’s description, TILs face stresses during manufacturing and within an immunosuppressive tumor environment. The company proposes using immune-stimulating cytokines to support activity, while regulating their expression to manage toxicity. The term armored refers to adding such functional capability to the cells. It describes a proposed engineered feature and carries no assurance that a particular construct will produce durable tumor control or an acceptable safety profile in people.

One company illustration concerns IL-12, a potent immune-stimulating cytokine. The engineering objective is to permit useful payload activity without excessive expression. The proxy describes production of regulated IL-12 levels from human cells using the optimized tamoxifen-sensitive system. Those experimental observations support investigation of expression control. Clinical development would also need to characterize the cells, the cytokine’s behavior, the control drug and the combined treatment conditions.

The desired balance is especially consequential for a living-cell therapy. Cells can change state, distribute across tissues and persist after administration. An external regulator is attractive when it provides reliable adjustment of the engineered function, but its performance must be understood across that changing cellular context. Senti’s proposed platform would need to link a manageable control-drug exposure to a reproducible payload response. Any useful range must remain compatible with the cells’ intended antitumor activity and the patient’s overall tolerance.

Manufacturing introduces another set of questions. Expanding a patient’s tumor-derived cells is different from producing a standardized small-molecule medicine. Adding a gene-expression control element can introduce further process and analytical work. The retained program has no selected candidate, clinical study population, validated commercial process or announced registrational path. The current opportunity is a research platform that may support future candidates if the company or a partner can supply the scientific and financial work.

The assignment agreement gives the listed company rights supporting this field of development, together with relevant know-how and research contracts. The service agreement provides a route for work and support through Opco. These contracts matter because a technical concept has value only alongside the ability to develop it. With limited cash and a discovery-stage program, a future partnership, license or corporate transaction could become as consequential as an individual laboratory result. The November risk discussion explicitly includes strategic alternatives involving the retained programs.

TIL, cytokine and IL-12 research descriptions · Assigned program rights · Candidate status and strategic alternatives.

07 SENTI-202 after the divestiture: clinical history and remaining CVR exposure

SENTI-202 was the former group’s lead clinical program. Its design combines engineered natural killer cells with logic-gating features intended to direct activity against cancer cells while limiting damage to selected healthy cells. The former company’s clinical work in relapsed or refractory acute myeloid leukemia provided the main source of clinical visibility before the sale. That history explains why SENTI-202 remains prominent in discussion of SNTI, even though ownership and control of the program have changed.

The logic-gating concept responds to different biological signals rather than treating a single marker as sufficient in every circumstance. Senti’s platform descriptions distinguish activating signals associated with target cells from protective signals intended to spare healthy cells. These designs pursue a wider therapeutic window. A program’s actual benefit and toxicity depend on the full construct, manufacturing, patient population, dose and treatment context. Platform labels alone do not determine a clinical outcome.

The October transaction transferred the clinical business to the buyer through Midco and Opco. Future SENTI-202 development spending and decisions belong in that acquired structure rather than the current listed company’s retained-program budget. The listed company warns that it and CVR holders have limited influence over development. A potential SENTI-202 success therefore has two separate economic destinations: the buyer’s ownership interest in the business and the milestone payments due under the executed CVR arrangement if its conditions are met.

The CVR arrangement preserves only specified cash-payment opportunities. It gives no general participation in the value of all sold assets, no shares of the buyer and no dividend or voting rights in Midco. Qualifying rightsholders can receive a pro rata share of defined milestones, within an aggregate cap and deadline. The economic value of a clinical program beyond those milestones belongs to the purchaser and its affiliates. This allocation is central to understanding why an old clinical development story is no longer the complete common-stock story.

The historical regulatory progress of SENTI-202 also remains specific to that program. A designation or clinical observation attached to the transferred asset cannot be applied to a future Rett or TIL candidate. The retained programs have no selected development candidate. The current SNTI calendar therefore lacks a comparable patient readout or marketing-application timetable. Its next concrete events concern the split, potential warrant claims, funding and listing status.

For CVR holders, the relevant long-term questions concern continued development, eventual application acceptance, approval, commercialization and Midco’s ability to pay. For common holders who acquired shares after the record date, the relevant research assets are the retained Regulator Dial programs and any subsequent transactions. Some investors may own both shares and historical rights, but each interest retains its own terms. Their exposure follows the instrument and eligibility date, not the fact that all of the history can be associated with the Senti name.

Historical platform and program descriptions · Transfer of clinical business · Executed CVR economics · Current program perimeter and risk factors.

08 CVR terms: three milestones, an aggregate cap and a separate obligor

The CVR Agreement dated October 21, 2026 creates contractual contingent rights administered through a rights agent. The maximum across all rights is $60 million, divided among three specified milestone categories. A holder’s amount depends on the agreement’s pro rata allocation and applicable adjustments. The maximum is an aggregate contractual ceiling, not an amount payable on each right and not cash already earned by the listed company.

The first category is $10 million on filing and FDA acceptance of a biologics license application for SENTI-202, or passage of the sixty-day review period without rejection. This milestone concerns acceptance for review, which is an earlier regulatory step than approval. It has no announced submission date in the current holding-company materials. Achievement requires the relevant application and the contractual acceptance condition rather than the existence of promising trial data or an intention to pursue registration.

The second category is $20 million on FDA approval of that BLA. Approval depends on a complete development and regulatory package acceptable to the agency. The third is $30 million after cumulative worldwide net sales of SENTI-202 exceed $200 million. That sales condition introduces both approval and commercial-execution exposure. Sales milestones concern actual defined net sales, not an addressable-market estimate, a distribution agreement or management’s assessment of eventual demand.

Each milestone must occur by the seventh anniversary of closing. The agreement’s notice, deposit and distribution provisions govern payment after an achieved milestone. The period permits development to continue over years, but also imposes an expiration boundary. A right can ultimately have no payment if the relevant conditions are never met within that period. Milestone success remains dependent on scientific, manufacturing, regulatory and commercial events outside the listed company’s direct control.

Midco is the payment obligor. The November quarterly report emphasizes that the rights are not guaranteed by the buyer or the listed company. This adds counterparty and enforcement considerations to the development conditions. The merger agreement contains diligent-efforts provisions and restrictions on actions primarily intended to avoid milestones or payments. Those contractual protections coexist with the uncertainties of development and counterparty resources; they do not turn conditional payments into an unconditional purchase price.

The board fixed the close of business on October 30 as the distribution record date. Historical common holders qualifying on that date receive the applicable rights. Equity awards and warrants have separate treatment under their terms. Purchases of common shares after that date bring ownership in the listed company without automatically recreating a historical CVR entitlement. The rights are unlisted and generally nontransferable, subject to specified exceptions such as permitted transfers. They have no ordinary exchange-traded price discovery mechanism.

The agreement also states that CVRs have no voting or dividend rights and are not ownership interests in the buyer, Midco or their affiliates. Their potential value is bounded by contractual payment conditions, rather than a residual claim on every future profit of the sold business. The tax discussion describes uncertainty over receipt and eventual payment treatment. That issue is specific to holders’ circumstances and is another reason the rights and the current common shares require separate economic descriptions.

Final CVR agreement, payment mechanics and restrictions · October 30 record date · Guarantee, eligibility and development risks.

09 SNTI earnings and six-quarter finances before the clinical-business sale

The financial history covers six consecutive quarters from the second quarter of 2025 through the third quarter of 2026. It describes the former consolidated group, including the subsidiaries that were subsequently transferred. Cash is the reported quarter-end balance of cash and equivalents, without restricted cash. R&D, G&A and net loss concern each individual quarter. Operating cash use is the amount absorbed by operating activities during that quarter, shown as a positive use of funds in the table.

QuarterCashR&DG&ANet lossOperating cash use
Q2 2025$21.576M$10.029M$6.769M$14.733M$13.073M
Q3 2025$12.243M$10.516M$6.432M$18.126M$9.446M
Q4 2025$16.420M$7.760M$5.846M$14.467M$6.875M
Q1 2026$8.935M$5.281M$6.233M$4.221M$7.481M
Q2 2026$6.463M$7.767M$6.739M$12.750M$14.249M
Q3 2026$5.553M$6.068M$6.273M$11.586M$6.727M

Quarterly operating cash use is derived from cumulative statements. For 2025, first-half use of $27.123 million less first-quarter use of $14.050 million gives second-quarter use of $13.073 million. Nine-month use of $36.569 million less the first-half amount gives third-quarter use of $9.446 million. Full-year use of $43.444 million less nine months gives fourth-quarter use of $6.875 million. These differences isolate the quarters without turning year-to-date amounts into quarterly figures.

For 2026, first-quarter operating cash use was $7.481 million. First-half use of $21.730 million less the first quarter gives $14.249 million in the second quarter. Nine-month use of $28.457 million less the first half gives $6.727 million in the third quarter. The calculation uses operating cash flow rather than the change in the bank balance, which also reflects financing, investing and other cash movements. The distinction is visible in periods when new financing partly offsets operating spending.

Fourth-quarter 2025 income-statement amounts are full year less nine months: R&D of $37.586 million less $29.826 million equals $7.760 million; G&A of $26.163 million less $20.317 million equals $5.846 million; net loss of $61.438 million less $46.971 million equals $14.467 million. Other quarterly expense and loss figures are presented directly as three-month periods in the relevant filings. All calculations use the reported thousands before rounding into millions.

The September 2026 balance sheet reported $5.553 million cash, $28.359 million total assets, $37.963 million liabilities and a $9.604 million stockholders’ deficit. Those balances preceded the completed sale. They include operating assets, leases and obligations within the old consolidated perimeter. Substantially all September cash was held in Midco and Opco and transferred with those entities. Applying the old group’s operating cash consumption to that balance would describe neither the current holding company’s bank balance nor its new cost structure.

Changes in reported loss also require attention to noncash and unusual items. The first nine months of 2026 included a $6.882 million gain on lease modification. That accounting gain reduced reported operating expense without representing recurring product revenue or a new financing source. The company had no product-sales franchise funding its research. The historical figures show sustained dependence on capital and other resources during development, while the post-closing funding question must be analyzed from the new perimeter and actual subsequent transactions.

Second-quarter 2025 statement · First-quarter 2025 cash flow · Nine-month 2025 statement · 2025 annual statement · First-quarter 2026 statement · First-half 2026 statement · Nine-month 2026 statement and subsequent perimeter.

10 Post-closing cash: placement funding, conditional commitments and going concern

The post-closing funding picture begins with a separate October 21 subscription by CPIF II-7 Limited, an affiliate of Celadon. The company issued 7,309,941 pre-split common shares at $0.342 per share, raising approximately $2.5 million. This supplied capital to the listed entity alongside the divestiture. It was equity financing with corresponding issuance, rather than proceeds from selling the clinical business for cash. The merger consideration remained contingent rights allocated to eligible holders.

An unaudited pro forma table accompanying the closing filing helps explain the structure but uses a June 30 starting balance. Its historical cash of $6.463 million is adjusted by removing $5.863 million associated with the disposed entities and adding the $2.5 million placement, producing $3.100 million pro forma cash. That is a hypothetical presentation at the stated historical base date. Cash spent, received or retained between that base date and the actual closing changes the real balance, so the pro forma number is not an observation of November cash.

The November 9 equity commitment is with CPIF II-9 Limited, a different affiliate from CPIF II-7 in the October placement. It provides for purchases at the company’s option, subject to conditions, totaling up to $4.55 million through the end of 2027. The scheduled maximums are $1.8 million by December 31, 2026, $1.35 million by March 31, 2027, $0.5 million by June 30, $0.5 million by September 30 and $0.4 million by December 31, 2027. The installments are prospective funding opportunities rather than a single amount already deposited.

The conditions matter operationally. The November filing identifies continued Nasdaq Capital Market listing, continued employment of specified executives, required stockholder approvals and registration rights among the requirements. Pricing follows the agreement’s Nasdaq Minimum Price definition. Shares issued through the arrangement would bring cash at the cost of additional ownership dilution. The company’s ability to access each installment therefore links capital availability to corporate conditions that also feature prominently in its risk disclosures.

Management states that existing resources may be insufficient to maintain current operations past the second quarter of 2027 and retains substantial doubt about the company’s ability to continue as a going concern. That assessment includes the changed operating structure and plans to obtain capital. It is the relevant disclosed liquidity warning for the post-merger company. A simple extrapolation from the old consolidated cash-flow series would obscure the asset transfer, the placement, service costs and contingent funding conditions.

Unexpected payments could shorten the available period further. The warrant cash-purchase right is particularly significant because its possible amount can exceed the limited cash base. Consulting obligations, public-company costs and transaction expenses also consume resources even while internally conducted research is limited. A funded plan for selected scientific work, clear resolution of cash claims and successful access to committed financing would improve visibility. Until those conditions are resolved, resource adequacy remains dependent on assumptions and further actions rather than a fully funded development program.

October placement and completed transaction · June-based unaudited pro forma · November commitment and affiliate · Current liquidity assessment and going concern.

11 SNTI share dilution, note exchange and warrant cash-purchase risk

The pre-split common-share count increased sharply during the transaction sequence. The September 30 balance sheet reported 31,145,390 common shares outstanding. The cover of the November quarterly report gives 85,706,263 outstanding on October 30. The October placement and exchange of outstanding notes into common stock explain the main expansion. The dates identify different capital structures even before the later reverse split changes the nominal share unit.

The company required exchange of $16 million of outstanding notes at $0.342 per share, effective October 28. The closing pro forma used an estimate of 46,783,626 exchange shares. Together with 7,309,941 placement shares, that is approximately 54.1 million additional shares, with the filing describing the combined increase as approximately 173.7%. The note exchange removes the exchanged principal from its old debt form while shifting the economic claim into common ownership. It changes both the balance of claims and the distribution of voting power.

The November 18 one-for-thirty-three split applies a different operation to the resulting common base. Each block of thirty-three issued shares is combined into one, subject to rounding. Options, warrants and other affected instruments adjust according to their terms. A consistent capital description keeps the pre-split issuance numbers and contractual prices together. A post-split share count uses the corresponding adjusted unit, with actual outstanding shares ultimately affected by fractional rounding and any additional issuances.

The December 2024 warrants cover 31,735,500 pre-split shares at a pre-split contractual exercise price of $2.30 in the November risk discussion. Celadon holds warrants covering 14,665,500 of those shares. Ordinary exercise and a Fundamental Transaction purchase election are different contractual mechanisms. Under the latter, a holder can require the company to purchase an unexercised warrant for its defined Black-Scholes Value. The contractual purchase value includes specified inputs and is not limited to the warrant’s immediate exercise value.

Senti believes that the merger qualified as a Fundamental Transaction. It identifies November 20, 2026 as the deadline for purchase elections. Payment would be due within five trading days after the later of the election and closing. The filing warns that demands could represent a significant portion of available cash or exceed it. The precise obligation depends on holder elections and contractual valuation. No reliable aggregate settlement amount follows from multiplying the number of underlying shares by an exercise price or a quoted common-share price.

Failure to satisfy an elected purchase could result in claims or breach of warrant terms. The company lists possible consequences including financing on unfavorable terms, curtailment of operations and potential dissolution or bankruptcy. These are disclosed risk outcomes rather than an announcement that any has occurred. The timing places potential warrant payments alongside a reverse split, listing deficiencies and prospective funding conditions, making cash preservation and resolution of claims central near-term execution issues.

The commitment for further common purchases creates additional issuance capacity under specified conditions. Celadon’s controlling position makes the financing counterparty and the governance relationship unusually connected. Additional equity can support public-company survival and research while reducing other holders’ percentage ownership. Any future strategic transaction could introduce further changes in capital and control. The relevant assessment combines cash received, obligations removed or added, voting concentration and the rights of each instrument, rather than the common-share count in isolation.

Dated share counts, exchange, control and detailed warrant risks · Placement and note-exchange terms · Future common-share purchases · Share consolidation mechanics.

12 Management, Celadon control and dependence on the former operating company

Timothy Lu, M.D., Ph.D., serves as chief executive officer, and Jay Cross is chief financial officer in the November quarterly report. The executives and supporting personnel operate within a structure that links the public holding company to its former operating subsidiary. The company warns that officers divide their time between the entities. Their continuing scientific and organizational knowledge can support the transition, while shared responsibilities create allocation and conflict-of-interest questions.

Celadon and its affiliates control approximately 67.7% of the outstanding common stock after the placement and note exchange, according to the November risk discussion. The listed company also qualifies as a controlled company under Nasdaq rules. That concentration can determine the outcome of many votes and influence financing, management and strategic decisions. The interests of the controlling holder may differ from those of other common stockholders, particularly when the controller or its affiliates participate on both sides of a transaction.

Related-party relationships extend beyond common ownership. The buyer controls the acquired clinical business; Opco provides substantially all operational support to the listed company; Celadon affiliates supplied placement capital and the later commitment; and Celadon holds a substantial portion of the December 2024 warrants. Each relationship has its own executed agreement. Their overlap creates practical dependence on counterparties whose incentives combine ownership, funding, services and rights under outstanding instruments.

The consulting arrangement supplies an initial operating framework for corporate administration and research-related support. The agreement’s twelve-month initial term and extension option provide a transition period. The ability to terminate individual services offers flexibility as internal capabilities develop. At the same time, a company with limited cash and no internally conducted research for approximately six months has restricted immediate alternatives if service availability, personnel attention or priorities change.

The November risk discussion also addresses earlier internal-control weakness and the risk associated with outsourced finance and accounting personnel. A small organization still needs accurate reporting, timely filings, cash controls and clear handling of related-party obligations. Completion of the sale and a timely quarterly filing are concrete corporate actions, while reliable ongoing reporting and independent oversight remain recurring responsibilities. These governance functions affect the company’s ability to access future capital and retain listing eligibility.

The risk discussion raises the possibility that the company’s reduced activities and asset base could attract shell-company scrutiny. Such a determination could constrain capital raising and resale of securities, while a future reverse merger could trigger initial listing requirements for the combined company. The November quarterly cover still checks the box indicating that the issuer is not a shell company under the SEC definition. The disclosed risk and the current cover response address different aspects of the situation; no completed adverse classification is announced in that filing.

The board is evaluating strategic alternatives, including acquisitions, licensing, mergers, reverse mergers and dispositions of retained programs. These possibilities describe a range of potential directions, not an announced transaction with agreed economics. A future deal could substantially change the business, management and ownership represented by current shares. With a concentrated controller and a small retained research base, the terms and governance of any such transaction would be central to evaluating its consequences for minority holders.

Officers, control, operational dependence and strategic alternatives · Consulting terms · Related-party capital commitment.

13 Merlintrader Health Score, red flags and the next evidence that matters

Senti’s financial and operating robustness is constrained by the changed asset base, going-concern uncertainty, conditional funding and unresolved listing issues. The assessment uses the current public holding company rather than the former clinical developer. A completed sale, retained research rights and an affiliate funding commitment provide a framework for continued activity. The immediate cash and governance constraints keep that framework fragile until more resources and a defined operating plan are secured.

The most consequential near-term evidence concerns trading on a split-adjusted basis after the November 18 split, any warrant purchase elections, actual funding receipts and Nasdaq’s response to the compliance plan. A share consolidation alone offers limited information about the company’s ability to pay its obligations or advance a program. Actual cash claims and funding conditions determine how much operating flexibility remains after the immediate corporate events.

Scientific progress would become more tangible with a selected candidate, detailed disease-relevant experiments and a funded development plan. The current Rett and TIL programs have no selected candidate or clinical results. Their underlying reporter and expression-control work provides a rationale for research, while the company expects reliance on collaborators and the former operating subsidiary during the transition. The timing of that organizational plan differs from a regulatory milestone.

For financial comparisons, the six-quarter table remains a record of the former consolidated business. A future post-closing statement would give a clearer view of the holding company’s actual assets, service costs, financing receipts and liabilities. Separate disclosure of any warrant settlement would be especially informative. The historical September balance, the June-based pro forma and the maximum equity commitment each measure a different part of the transition and cannot be combined into an observed cash balance.

The current case therefore rests on conditional corporate survival and early scientific optionality. It has concrete dates and contracts, but substantial uncertainty around resources and eventual therapeutic value. The quality of subsequent execution will be visible in actual receipts, resolved obligations, continued reporting and clearly described scientific decisions. The score is a dated assessment of robustness, not an estimate of a future share price or the chance that a specific experimental treatment will succeed.

Financial, operating and governance assessment · Conditional financing · Immediate corporate timetable · Milestone limits.

Merlintrader Health Score · $SNTI

1.20out of 5
Balance sheet and runway · 30%1.0

The November 16, 2026 filing retains substantial doubt about going concern and says operations may not be maintained past Q2 2027. The October placement raised approximately $2.5 million. The later $4.55 million commitment is conditional future equity funding. September consolidated cash of $5.553 million preceded the divestiture, and substantially all was held in the transferred entities. Potential warrant cash-purchase demands add immediate pressure.

Catalyst · 30%1.5

The one-for-thirty-three split became effective on November 18, 2026, with split-adjusted trading expected from November 19. November 20 is the warrant-purchase election deadline stated in the quarterly report. Conditional funding windows and Nasdaq compliance decisions follow. The retained Rett and TIL programs have no selected development candidate or announced patient-data timetable.

Dilution · 20%1.0

Common shares increased from 31,145,390 on September 30, 2026 to 85,706,263 on October 30, before the one-for-thirty-three split effective November 18. The October placement and exchange of $16 million notes expanded ownership claims. Future commitment purchases can add shares, while Celadon and affiliates control approximately 67.7%. The split changes the trading unit rather than the underlying financing requirements.

Liquidity · 10%1.0

SNTI remained Nasdaq Capital Market-listed on November 17, 2026, with both bid-price and stockholders’ equity deficiencies. A reverse split became effective on November 18, and the quarterly report says Nasdaq had not accepted the compliance plan. Concentrated ownership, changing share units and potential listing loss can impair market depth and execution.

Execution · 10%1.5

The company completed the clinical-business sale and executed assignment and consulting agreements on October 21, 2026. The retained business depends on Opco and outside collaborators, with no internally conducted R&D expected for approximately six months. Candidate selection, scientific validation, funding receipts and listing compliance remain ahead. Shared management and related-party dependence constrain operating independence.

Assessed on November 17, 2026; reviewed on November 18, 2026 after the Form 8-K confirming the split, with no change to any pillar score because the split changes the share unit without adding resources or resolving the listing deficiencies. Weighted calculation: 1.0 × 30% + 1.5 × 30% + 1.0 × 20% + 1.0 × 10% + 1.5 × 10% = 1.20 out of 5. The score describes financial and operational robustness over twelve to eighteen months. It is not an investment recommendation or a probability of clinical success.

Current balance sheet, capital, development and governance risks · Completed transaction · Conditional financing · Listing-related corporate event · Split effectiveness.

SNTI red flags

  • The retained Rett and TIL programs are discovery-stage, without selected development candidates or patient-data timetables.
  • SENTI-202 and substantially all former clinical operations belong to the buyer after October 21.
  • Shares acquired after October 30 lack the historical CVR entitlement; milestone payments are conditional obligations of Midco.
  • Substantially all September consolidated cash was held in transferred entities; the old cash balance and burn do not measure current runway.
  • Future equity installments depend on conditions including continued listing and can cause additional dilution.
  • December 2024 warrant purchase elections could create cash demands exceeding available funds.
  • Bid-price and stockholders’ equity deficiencies remain distinct Nasdaq issues.
  • Celadon affiliates control approximately 67.7%; shared management and dependence on Opco create conflicts and operating constraints.

SNTI Stock FAQ: Senti Biosciences Holdings Questions Answered

When is the next SNTI stock catalyst?

As of November 18, 2026, SNTI’s one-for-thirty-three reverse split had become effective at 5:00 p.m. ET, with split-adjusted trading expected from the November 19 opening. November 20 is the separate warrant cash-purchase election deadline stated in the quarterly report. Conditional funding and Nasdaq compliance events follow; the retained discovery programs have no announced patient-data release date. Split 8-K · Split timetable · Warrant and development calendar.

Does Senti Biosciences have an FDA-approved treatment?

As of November 17, 2026, Senti Biosciences Holdings had no approved treatment and no selected development candidate for its retained Rett or TIL programs. SENTI-202 and the former clinical business transferred to the buyer on October 21. Eligible historical CVRs concern conditional milestones for that transferred program. Current business and regulatory risks · Completed transfer.

How much cash does Senti Biosciences have?

SNTI raised approximately $2.5 million in an October 21, 2026 placement and obtained a conditional future equity commitment of up to $4.55 million on November 9. These amounts differ from an observed current cash balance. Substantially all September consolidated cash of $5.553 million belonged to transferred entities. Going-concern doubt and potential warrant cash demands remain. Placement · Commitment · Liquidity risk.

What dilution risks affect SNTI stock?

SNTI had 85,706,263 common shares outstanding on October 30, 2026, before the reverse split effective November 18, versus 31,145,390 on September 30. The placement and note exchange expanded the share base. Future conditional equity purchases can issue more shares, and Celadon affiliates control approximately 67.7%. A reverse split changes the share unit while funding requirements remain. Capital structure and ownership.

When does Senti Biosciences report earnings?

SNTI filed its latest quarterly earnings report on November 16, 2026, covering September 30; its next earnings date remained unannounced as of November 17. Q3 net loss was $11.586 million, R&D expense $6.068 million and G&A expense $6.273 million. These results include the former consolidated business before the October sale. Latest quarterly report.

What does Senti Biosciences Holdings do?

As of November 17, 2026, Senti Biosciences Holdings retained discovery-stage Regulator Dial programs for Rett syndrome and armored tumor-infiltrating lymphocyte therapies. It had transferred SENTI-202 and substantially all former clinical operations to the buyer. The retained technology seeks small-molecule control over gene expression; neither retained program had a selected development candidate. Current business · Regulator Dial research.

Do new SNTI shares include the SENTI-202 CVRs?

SNTI shares acquired after the October 30, 2026 record date do not include the historical CVR entitlement. Eligible rights can receive a pro rata share of up to $60 million aggregate if specified SENTI-202 milestones occur within seven years of closing. The unlisted rights are obligations of Midco, with no payment guarantee from the buyer or listed company. Record date · CVR agreement · Holder risks.

Is SNTI doing a reverse stock split?

On November 17, 2026, SNTI announced a one-for-thirty-three reverse split; a Form 8-K filed November 18 confirms that it became effective at 5:00 p.m. ET that day, with split-adjusted trading expected from November 19 under the existing symbol and new CUSIP 816944201. Fractional entitlements are rounded upward. Outstanding equity instruments adjust under their terms. The company continues to face a separate stockholders’ equity listing deficiency alongside its bid-price issue. Split 8-K · Split announcement · Listing risks.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $SNTI or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data or decline to file an application, and companies that spend ahead of revenue raise equity at whatever price the market will bear. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate. Investors may lose part or all of their capital.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.